The kit detects 29 mutations in exons 18, 19, 20, and 21, and has a limit of mutation detection at .1 percent in a background of wild-type DNA.
The scientists hope to incorporate the method, which can measure endogenous peptides at zeptomolar concentrations, in clinical trials starting next year.
Curetis and BGI subsidiary MGI Tech plan to develop NGS-based diagnostics for microbial infections on the MGISeq instrument for the Chinese market.
The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.
The device allows researchers to track cancer growth for a longer period of time, enabling improved observations and analysis, according to the researchers.
The team used CRISPR to inactivate a gene in colon organoids, and found that a specific DNA repair defect underlies a mutational signature in some cancers.
The study, which looked at 41 breast cancer cell lines, suggests that such an approach could enable higher-throughput protein-protein interaction work.
Researchers identified unique ALK rearrangements in patients that lack previously known indicators of mesothelioma.
Tempus will provide molecular sequencing and data analysis for patients with metastatic or incurable cancer enrolled in a Cleveland Clinic study.
GenomeDx will have exclusive rights to distribute the molecular tests in most of the US, while Pathnostics continues to perform the assays in-house.
PerkinElmer Genetics will provide clinical whole-genome sequencing, data interpretation, and diagnostic reports to IDG for patients with neurological disorders.
The probes let researchers analyze oligomeric aggregates linked to forms of amyloidosis and could aid early diagnosis or monitoring response to therapy.
Swedish Cancer Institute has enlisted machine-learning technology vendor GNS Healthcare to model patient-specific breast cancer tumor data.
Enpicom will initially offer separate solutions on its ImmunoGenomiX platform for research and clinical applications in oncology but seeks to expand into other disease areas.
Researchers saw mismatch repair-related mutations in a significant subset of breast cancers, hinting at potential response to checkpoint blockade immunotherapy.
Genomic Health will gain exclusive worldwide rights to develop and sell an IVD version of its Oncotype DX breast cancer test on Biocartis' Idylla platform.
The firm will hold the intellectual property for its cell capture and analysis technology as QMUL files patents for recent findings using the Parsortix system.
The group is proposing women ages 30 to 65 be screened with cervical cytology every three years or receive testing for high-risk HPV every five years.
The company shared validation data this week that it said led the FDA to approve use of the test in a new prospective trial of Roche's Tecentriq in NSCLC.
The company said that it plans to use the funds to develop NGS assays in the oncology and precision medicine space, and expand its US commercial team.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.